Jeito Capital Closes Record $1.2 Billion Jeito II Fund for European Biopharma Investments
Friday, April 17, 2026
Paris-based Jeito Capital has achieved a landmark milestone in the European biopharma investment landscape by successfully closing its second fund, Jeito II, at $1.2 billion. This fundraising effort surpasses the fund's original target and establishes it as the largest capital raise ever completed by an independent, biopharma-focused fund in Europe. The announcement underscores the growing confidence among institutional investors in Europe's potential to lead in innovative drug development and life sciences ventures.
Jeito Capital, founded in 2020 by experienced biotech entrepreneurs including Philippe Auvray and Jean-Francois Formela, specializes in providing flexible capital to high-potential biopharma companies at critical stages of development. The firm's unique investment thesis emphasizes supporting companies from late discovery through to late-stage clinical development, bridging gaps often overlooked by traditional venture capital models. With Jeito II, the fund aims to back 25-30 portfolio companies, focusing on transformative therapies in oncology, immunology, neurology, and rare diseases—areas where Europe has demonstrated strong scientific expertise.
This closure comes at a pivotal time for the European life sciences sector, amid evolving regulatory frameworks and increased emphasis on biomanufacturing sovereignty. The European Union's Pharma Package and initiatives like the European Biotech Act are fostering an environment conducive to innovation, while challenges such as supply chain resilience and talent retention persist. Jeito's success signals robust investor appetite for European biopharma, contrasting with global market fluctuations and highlighting the region's competitive advantages in R&D infrastructure, clinical trial networks, and access to top-tier research institutions like INSERM in France and the Crick Institute in the UK.
The fund's oversubscription reflects commitments from a diverse investor base, including prominent European pension funds, family offices, and international limited partners. Notably, Jeito II builds on the track record of its debut fund, Jeito I, which deployed over €400 million into 18 companies, achieving notable clinical milestones such as the advancement of candidates into Phase II and III trials. Key portfolio successes include partnerships with big pharma players, validating Jeito's hands-on approach to value creation through operational expertise and strategic guidance.
Looking ahead, Jeito Capital plans to deploy capital selectively, prioritizing companies with robust data packages and clear paths to regulatory approval via the EMA. This strategy aligns with broader industry trends toward data-driven investments and AI-enhanced drug discovery. As Europe ramps up efforts to reduce reliance on Asian supply chains and bolster domestic manufacturing, funds like Jeito II are poised to catalyze growth in contract development and manufacturing organizations (CDMOs) and advanced therapy medicinal products (ATMPs).
Industry analysts view this raise as a bullish indicator for 2026, potentially spurring a wave of follow-on investments and M&A activity. With Europe's life sciences market projected to grow at a CAGR of 7-9% through the decade, driven by biotech innovations and digital health integrations, Jeito's capital infusion will empower startups to navigate clinical trial complexities under the new Clinical Trials Regulation (CTR). Furthermore, the fund's focus on sustainability and patient access strategies positions it to address payer pressures in national health systems across the EU27.
In the context of recent regulatory developments, such as the European Health Data Space (EHDS) and updated State Aid rules for R&D, Jeito II's launch enhances Europe's attractiveness as a hub for biopharma entrepreneurship. Stakeholders, including pharma executives and regulators, anticipate that this influx of capital will accelerate the translation of academic breakthroughs into marketable therapies, ultimately strengthening the continent's global competitiveness against U.S. and Asian counterparts.
The closure of Jeito II not only validates Europe's maturing venture ecosystem but also sets a benchmark for future funds, encouraging more LP participation in high-risk, high-reward biopharma ventures. As deployment begins, market watchers will track early investments for signs of portfolio synergies and exit opportunities via IPOs on Euronext or acquisitions by multinational pharma giants.
